You're at home, looking at the scales and wondering whether orlistat could help, or whether your BMI is too low, too high, or on the wrong side of a prescribing rule. The answer isn't just a number. In the UK, a prescriber considers your BMI alongside weight-related conditions, previous attempts to lose weight, medicines, medical history, and whether orlistat is suitable for the way you're managing food and activity.

The medicine is also not a general slimming tablet for anyone who wants to lose a few pounds. It's a treatment used within a wider weight-management plan, and the same eligibility rule can lead to a different decision depending on your health and medicines. Here's how a UK clinician is likely to work through the question, who can take orlistat.

Table of Contents

• Is Orlistat the Right Option for You
• UK BMI and Age Criteria for Orlistat
  • What BMI tells you
• Weight-Related Conditions That Lower the BMI Threshold
  • What counts as a qualifying condition
• Borderline Cases and the 2025 NICE Specialist Pathway
  • Why the pathway matters
• Who Should Avoid Orlistat and Key Drug Interactions
• Monitoring, Follow-Up and When to Speak to a Clinician
  • What clinicians may check
• A Practical Checklist Before You Ask About Orlistat

Is Orlistat the Right Option for You

Start with the practical question, not the brand name: what problem are you trying to solve? Orlistat reduces the absorption of some dietary fat in the gut. A useful analogy is a sieve. It lets some nutrients through while allowing part of the fat to pass out in the stool. It doesn't switch off appetite, change your metabolism instantly, or replace meal planning and movement.

A clinician will usually work through several points:

1. Your current measurements and weight history. A recent height and weight help establish BMI, but the pattern over time matters too. Weight gain linked to another medicine, a health condition, reduced mobility, or major life change may need a broader response than orlistat alone.
2. What you've already tried. UK guidance has historically placed orlistat after a non-drug attempt involving diet and increased physical activity. Older NICE-endorsed criteria included losing at least 2.5 kg before treatment began, as described in the historical review of UK prescribing guidance (historical NICE criteria). Current decisions still sit within an organised weight-management plan.
3. Whether you're ready for the food changes. Orlistat works alongside a reduced-fat diet. If meals are consistently high in fat, unwanted effects such as oily stools, urgency and leakage become more likely. The medicine is therefore less like a magic switch and more like a tool that only works properly when the rest of the plan is in place.
4. Your medicines and medical history. The prescriber needs to know about prescribed medicines, pharmacy purchases, vitamins, herbal products, pregnancy plans, breastfeeding, digestive disorders, liver problems and transplant medicines.

A useful rule: meeting the BMI threshold means you can be assessed. It doesn't guarantee that orlistat is the right treatment.

You can also read a broader comparison of weight-loss tablets and how they differ, but don't use any online list as a substitute for an individual consultation. Similarly, supplements marketed as supplements to boost metabolic health aren't automatically safe or effective, particularly if you take medicines or have an underlying condition.

The final decision belongs to a prescriber. They'll check that the expected benefit is worth the practical disadvantages, explain how to take the medicine, and arrange a review rather than leaving you to judge success on side effects or daily scale changes.

UK BMI and Age Criteria for Orlistat

For most adults, BMI is the first gate. NHS guidance uses BMI 30 or above, or BMI 28 or above when a person also has a weight-related condition such as type 2 diabetes or hypertension (NHS orlistat guidance). NICE describes the same two thresholds and says orlistat can be prescribed in primary care and other settings when the criteria are met (NICE prescribing guidance).

What BMI tells you

BMI is calculated from weight in relation to height. It's useful as a screening measure because it gives prescribers a consistent starting point, but it doesn't show where body fat is stored, how much muscle you have, or how weight affects your health. A muscular person and someone with central adiposity can have the same BMI but different clinical risks.

That's why waist measurement and the wider health picture matter when BMI sits close to a threshold. A person just below the routine gate shouldn't assume the conversation is over, particularly if they have blood-pressure problems, abnormal glucose results, sleep apnoea or other complications. Specialist services may assess risk differently, as discussed below, but routine prescribing still follows the published thresholds.

Age needs a little care. Historical UK guidance referred to adults aged 18 to 75, while current NHS information focuses on adult eligibility and individual suitability. People under 18 generally need referral into an appropriate paediatric or specialist pathway. People over 65 aren't automatically ruled out, but a prescriber should check falls risk, frailty, diet quality, kidney and liver health, and the possibility of interactions.

There's also a product distinction. Prescription orlistat is commonly supplied as 120 mg, while a lower-dose 60 mg product is available from pharmacies without a prescription under the Xenical brand in UK consumer guidance. Availability and suitability aren't the same thing, so buying a lower-dose product doesn't remove the need to check contraindications or interactions. If you're comparing routes, review the difference between prescription weight-loss tablets and pharmacy options with a pharmacist or prescriber.

Weight-Related Conditions That Lower the BMI Threshold

The BMI threshold falls from 30 to 28 when excess weight is linked with a condition that could improve through weight management. The reason is clinical rather than cosmetic. A person with a lower BMI may still face substantial health consequences if weight is worsening blood pressure, glucose control, sleep or cardiovascular risk.

Conditions that may be relevant include:

• Type 2 diabetes, particularly where weight management forms part of the diabetes plan.
• Prediabetes or impaired glucose tolerance, confirmed through clinical testing.
• Hypertension, even when treatment has brought readings under control.
• Dyslipidaemia, meaning an unhealthy blood-fat profile.
• Established cardiovascular disease, where reducing weight may support broader risk reduction.
• Obstructive sleep apnoea, especially when excess weight contributes to airway obstruction.
• Polycystic ovary syndrome, where weight management may be part of a wider treatment approach.
• Some weight-affecting mental health conditions, when lifestyle change is clinically indicated and the person's mental-health care is being considered alongside weight treatment.

A BMI of 29 with documented, treated hypertension could therefore meet the headline threshold for assessment. A person with a BMI of 27.5 and newly diagnosed type 2 diabetes, however, falls below the standard BMI 28 boundary for routine orlistat prescribing and may need a more specialist discussion rather than assuming automatic eligibility.

What counts as a qualifying condition

The diagnosis should normally be recorded in your medical notes or supported by test results. Saying that you have “high sugar” or “borderline blood pressure” may prompt further checks, but it doesn't establish the prescribing criterion by itself. Bring letters, recent results and your current treatment list if you're being assessed outside your usual GP practice.

Central adiposity can complicate the picture. A waist measurement may show a health risk that BMI doesn't capture, but it doesn't automatically override the routine threshold. The clinician may decide that a structured lifestyle programme, investigation of glucose and lipid results, or a referral to a specialist service is more appropriate.

The threshold also assumes active participation in diet and activity advice. Orlistat isn't intended to compensate for an unchanged eating pattern. In practice, the prescriber will want to know whether you can follow the dietary approach, attend reviews and report side effects.

Borderline Cases and the 2025 NICE Specialist Pathway

A simple online rule can leave people in a confusing gap. Someone with a BMI between 27 and 29.9 and no documented weight-related condition may not meet routine UK criteria, while someone with a similar BMI and confirmed complications may need a different route. Central adiposity, rising cardiovascular risk, prediabetes and sleep apnoea can all make the clinical picture more serious than BMI suggests, but they don't automatically create a prescription.

The important distinction is between routine prescribing criteria and specialist obesity care. NICE's more recent guidance places orlistat alongside newer medicines within broader obesity-management pathways. Specialist services, often described through tier 3 and tier 4 care, can involve a multidisciplinary assessment with clinicians such as obesity physicians, dietitians, psychologists and surgeons. The team may review complications, previous treatment, functional health, eating patterns and whether a medicine fits the wider plan.

Why the pathway matters

The specialist route doesn't mean every person below BMI 28 can receive orlistat. It means a borderline case may deserve proper clinical assessment rather than a one-line rejection. NICE's 2025 to 2026 guidance package sets orlistat alongside newer medicines with more complex specialist eligibility requirements, which makes BMI-only summaries increasingly incomplete (NICE medicines guide).

People who may need a fuller discussion include:

• Adults with BMI 27 to 29.9, where risk factors are present but not yet clearly documented.
• People with a large waist measurement, even when BMI is just below the routine gate.
• Older adults near a threshold, where medication review and muscle preservation matter as much as weight.
• People who have had bariatric surgery, then reached a plateau or regained weight and need coordinated follow-up.

Private and online clinics may use a different consultation route, but the medicine's pharmacology doesn't change. A legitimate prescriber should still verify identity, measurements, medical history, contraindications and current medicines. Faster access doesn't justify weaker assessment.

If you're outside the standard criteria, ask your GP or existing weight-management team whether a specialist referral is appropriate. Don't exaggerate a diagnosis or rely on a self-calculated waist risk to obtain treatment.

Who Should Avoid Orlistat and Key Drug Interactions

Certain medical situations rule out self-starting orlistat. It is unsuitable during pregnancy or breastfeeding, and for people with chronic malabsorption syndrome, cholestasis, or a known hypersensitivity to orlistat or its ingredients. These situations require a clinician's assessment before starting orlistat.

Other conditions need a prescribing discussion because the medicine could be unsuitable or require closer observation. Tell the prescriber about gallbladder disease, previous pancreatitis, or significant liver impairment. Anyone who has received an organ transplant should also mention all transplant medicines, especially ciclosporin or tacrolimus. Orlistat can alter absorption, which can affect blood concentrations and transplant treatment.

The medicine limits absorption of dietary fat, so it can also reduce uptake of the fat-soluble vitamins A, D, E and K. Severe diarrhoea can make some medicines less reliable, including levothyroxine, amiodarone, antiepileptics, warfarin and oral contraceptives. The risk differs between medicines, so a full review of current treatment is important. The NICE CKS orlistat prescribing information was updated on 16 May 2025 and applies to users in the UK, Crown Dependencies and British Overseas Territories, making it a relevant UK clinical reference.

Bring every medicine packet to the consultation, including pharmacy products, vitamins and herbal supplements. The BNF interaction tables and your prescriber can distinguish “do not use” from “use with monitoring”, which broad eligibility summaries often miss.

Monitoring, Follow-Up and When to Speak to a Clinician

Orlistat should come with a review plan. Historical NICE guidance required a person to lose at least 2.5 kg through diet and increased physical activity before the first prescription, while current practice still treats the medicine as part of a structured weight-management programme (earlier NICE review record).

A review at 12 weeks is central to the decision. NICE guidance uses a stopping rule when weight loss is below 5% of starting weight, because continuing a medicine that isn't producing a useful response exposes you to inconvenience and risk without enough benefit. Don't change the dose or continue indefinitely because the capsules are still available.

What clinicians may check

Before and during treatment, the review may include:

• Weight and waist measurement, to assess the direction of change rather than one isolated reading.
• Blood pressure, especially if hypertension is part of the reason for treatment.
• Lipid profile, when cholesterol or triglyceride problems are relevant.
• HbA1c, where diabetes or impaired glucose regulation needs monitoring.
• Vitamin status, particularly vitamin D and the wider fat-soluble vitamin group where clinically indicated.
• Digestive effects and adherence, because oily stools, urgency and leakage can show that the dietary fat pattern needs adjustment.

Speak to a clinician promptly about rectal bleeding, severe abdominal pain, jaundice, dark urine, persistent oily stools with continuing weight loss, or symptoms that could indicate kidney stones. Don't dismiss these as normal treatment effects.

The outcome review may lead to continuation, adjustment, stopping, dietitian support, or assessment for another treatment. Options can include a more intensive specialist programme, a GLP-1 medicine where appropriate, or bariatric assessment. For people worried about liver health, a clinician can decide whether blood tests or another assessment is appropriate. A general guide to checking liver function at home shouldn't replace clinical testing or interpretation.

Clinical trial evidence supports modest rather than dramatic expectations. A NICE evidence review found pooled results favouring orlistat over placebo, with an average additional weight loss of 3.19 kg across the reviewed trials (NICE evidence review). That result helps explain why follow-up is important. If the medicine doesn't provide meaningful benefit for you, the plan should change.

A Practical Checklist Before You Ask About Orlistat

Use this checklist to prepare for a consultation, not to prescribe the medicine yourself. Write down the answers before you book an appointment, because accurate information helps the clinician make a safer decision.

1. Confirm your age. Routine adult assessment generally starts at 18. If you're younger, ask about an appropriate paediatric or specialist service rather than using an adult product.
2. Record current measurements. Use a recent weight and height to calculate BMI in kg/m². Note whether you're at BMI 30 or above, or at BMI 28 or above with a documented weight-related condition.
3. List relevant health conditions. Include type 2 diabetes, prediabetes or impaired glucose tolerance, hypertension, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea, polycystic ovary syndrome and relevant mental-health conditions. Mention waist concerns or central weight distribution even if you don't know whether they change eligibility.

4. Prepare a complete medicine list. Include prescriptions, painkillers, contraceptives, vitamins, supplements and transplant medicines. Mention levothyroxine, warfarin, amiodarone, antiepileptics, ciclosporin or tacrolimus specifically if you take them.
5. Rule out important safety concerns. Tell the clinician if you're pregnant, breastfeeding, planning pregnancy, or have malabsorption, cholestasis, gallbladder disease, pancreatitis, liver impairment or a transplant history.

Then ask focused questions: Why might orlistat suit me? What diet should I follow? What symptoms require help? When will we review progress? What happens if I don't meet the response target? The prescriber should set a starting plan, confirm the review interval and explain whether a specialist referral is more appropriate.

If you fall outside the routine BMI criteria, don't abandon the conversation. Ask whether your waist measurement, complications or treatment history justify specialist assessment. Conversely, if you meet the headline threshold, remember that eligibility doesn't override pregnancy, malabsorption, interactions or other safety concerns.

Don't stop orlistat abruptly without follow-up planning if you're already taking it. Speak to the prescriber about what replaces it, how to maintain the dietary work you've started, and whether another treatment or service should take over.

Trim provides medically supervised UK weight-management consultations, with clinicians assessing whether options such as orlistat or other treatments are suitable for your circumstances. Visit Trim to discuss your eligibility, medicines, support needs and next steps through a regulated online service.